Quantcast
Last updated on April 17, 2014 at 11:16 EDT

Latest Venlafaxine Stories

2009-05-12 07:00:00

Use of Atypicals In Major Depression Treatment Is Growing, According to a New Report from Decision Resources Patient-Flow Forecasts Between Pristiq and Effexor XR Need to Take Into Account Reimbursement Hurdles WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro is no longer the leading first-line agent of choice for the treatment of major...

2008-11-14 12:00:05

Lexicon Pharmaceuticals, a biopharmaceutical company, has successfully completed a second Phase I clinical trial of LX1032, an orally-delivered small molecule drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. Based on the results from this study, Lexicon is planning to initiate a Phase II study in patients with carcinoid syndrome. LX1032 will be Lexicon's third drug candidate to progress to Phase II clinical trials. Clinical development of LX1032 is...

2008-11-13 06:00:08

* Drug Candidate Will Advance to Phase 2 Clinical Trial in Carcinoid Patients * Potent Reduction in Serotonin Achieved * Drug Candidate Being Developed Under Fast Track Status From FDA THE WOODLANDS, Texas, Nov. 13, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has successfully completed a second Phase 1 clinical trial of...

2008-10-26 06:00:14

Auspex Pharmaceuticals has reported positive results from its Phase I clinical trial evaluating SD-254, a selective serotinin-norepinephrine reuptake inhibitor. Auspex is developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment of major depressive disorder. In the clinical study conducted in 16 healthy volunteers, SD-254 exhibited a pharmacokinetic profile that appears to be superior to that of venlafaxine and consistent with that required for increasing safety...

2008-10-17 09:00:06

RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced that it has initiated a Phase II clinical trial for its lead product candidate Tyrima(TM) for the treatment of major depressive disorder (MDD). Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A...

2008-10-15 09:00:48

COLLEGEVILLE, Pa., Oct. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today provided an update on its global strategy for desvenlafaxine for the treatment of major depressive disorder (MDD) in adults. Desvenlafaxine has already been approved for the treatment of MDD in adults in the United States, Australia and Brazil, and applications are currently pending in 22 markets. As part of its global regulatory strategy, and in consultation with the Committee for...

2008-10-09 12:00:39

Osmotica Pharmaceutical Corp. is announcing that Venlafaxine Extended-Release Tablets, 37.5 mg, 75 mg, 150 mg, and 225 mg, which was approved by the U.S. Food and Drug Administration in May, is now commercially available through its marketing partner, Upstate Pharma, LLC, a subsidiary of UCB, Inc. Shipments of the product to wholesalers and other commercial outlets began September 30, 2008 and promotion of the product will commence later in the month. Forrest Waldon, CEO of Osmotica...

2008-09-26 09:00:40

Adheris, Inc., a leader in patient adherence and education programs, announced today the results of a new study that examined adherence rates among patients on SSRI/SNRI antidepressant therapy. Study results showed that patients new to antidepressant treatment and those who had restarted therapy after a lapse of 6 or more months were twice as likely to discontinue therapy in the first 30 days of treatment versus patients previously dispensed an antidepressant. According to lead author...

68971040a3dc55896c39fbd3fdcb02311
2008-09-23 12:10:00

For some time, antidepressants and other drugs have been used collectively to treat hot flashes and other menopausal symptoms that can accompany breast cancer treatment. However, researchers said on Monday that ancient acupuncture methods work just as well as drugs and their effects tend to outlast drugs. Researchers compared acupuncture, which began in China more than 2,000 years ago, to Wyeth antidepressant Effexor, which is prescribed for hot flashes in breast cancer patients. Dr. Eleanor...

2008-09-11 03:00:08

By Klinger, Gil Merlob, Paul Abstract: Depression is common in women of childbearing age and especially during pregnancy and the postpartum period. Selective serotonin reuptake inhibitors (SSRIs) are increasingly being used to treat depression prior to and throughout pregnancy. Up to 30% of the newborn infants exposed to SSRIs may present with clinical signs during the first days after birth. Neonatal abstinence syndrome (NAS) describes this clinical syndrome resulting from prior prolonged...